Seeds as a Production System for Molecular Pharming Applications: Status and Prospects

Sabalza, Maite; Vamvaka, Evangelia; Christou, Paul; Capell, Teresa

doi:10.2174/1381612811319310009

Cited by 35 publications

(23 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, transgenic plants are ideal systems for low-cost and scalable production of recombinant proteins with the potential for the direct preparation and application of crude extracts (Stoger et al, 2014). Cereals such as rice and soybean are efficient platform for the production of microbicides as they allow high-level production of proteins in desiccated tissue, which therefore intensify stability during transport and storage, and seed extract inherently regarded safe as it is staple food crop (Sabalza et al, 2013). In the term of downstream process, the ability of production of protein body by cereals is a benefit as protein bodies are insoluble in low-salt aqueous buffers, and they can be easily purified by centrifugation.…”

Section: Lectinsmentioning

confidence: 99%

The potential of plant systems to break the HIV‐TB link

Habibi

Daniell

Soccol

et al. 2019

Plant Biotechnology Journal

View full text Add to dashboard Cite

Summary Tuberculosis (TB) and human immunodeficiency virus (HIV) can place a major burden on healthcare systems and constitute the main challenges of diagnostic and therapeutic programmes. Infection with HIV is the most common cause of Mycobacterium tuberculosis (Mtb), which can accelerate the risk of latent TB reactivation by 20‐fold. Similarly, TB is considered the most relevant factor predisposing individuals to HIV infection. Thus, both pathogens can augment one another in a synergetic manner, accelerating the failure of immunological functions and resulting in subsequent death in the absence of treatment. Synergistic approaches involving the treatment of HIV as a tool to combat TB and vice versa are thus required in regions with a high burden of HIV and TB infection. In this context, plant systems are considered a promising approach for combatting HIV and TB in a resource‐limited setting because plant‐made drugs can be produced efficiently and inexpensively in developing countries and could be shared by the available agricultural infrastructure without the expensive requirement needed for cold chain storage and transportation. Moreover, the use of natural products from medicinal plants can eliminate the concerns associated with antiretroviral therapy (ART) and anti‐TB therapy (ATT), including drug interactions, drug‐related toxicity and multidrug resistance. In this review, we highlight the potential of plant system as a promising approach for the production of relevant pharmaceuticals for HIV and TB treatment. However, in the cases of HIV and TB, none of the plant‐made pharmaceuticals have been approved for clinical use. Limitations in reaching these goals are discussed.

show abstract

Section: Lectinsmentioning

confidence: 99%

The potential of plant systems to break the HIV‐TB link

Habibi

Daniell

Soccol

et al. 2019

Plant Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…This decreases the overall cost of the production system (Sabalza et al, 2013). Cereals such as maize, barley, rice and wheat are important seed food crops that accumulate high levels of protein (Shewry & Halford, 2002).…”

Section: Seedsmentioning

confidence: 99%

Molecular farming on rescue of pharma industry for next generations

Moustafa

Makhzoum

Trémouillaux-Guiller

2015

Critical Reviews in Biotechnology

View full text Add to dashboard Cite

Recombinant proteins expressed in plants have been emerged as a novel branch of the biopharmaceutical industry, offering practical and safety advantages over traditional approaches. Cultivable in various platforms (i.e. open field, greenhouses or bioreactors), plants hold great potential to produce different types of therapeutic proteins with reduced risks of contamination with human and animal pathogens. To maximize the yield and quality of plant-made pharmaceuticals, crucial factors should be taken into account, including host plants, expression cassettes, subcellular localization, post-translational modifications, and protein extraction and purification methods. DNA technology and genetic transformation methods have also contributed to great parts with substantial improvements. To play their proper function and stability, proteins require multiple post-translational modifications such as glycosylation. Intensive glycoengineering research has been performed to reduce the immunogenicity of recombinant proteins produced in plants. Important strategies have also been developed to minimize the proteolysis effects and enhance protein accumulation. With growing human population and new epidemic threats, the need for new medications will be paramount so that the traditional pharmaceutical industry will not be alone to answer medication demands for upcoming generations. Here, we review several aspects of plant molecular pharming and outline some important challenges that hamper these ambitious biotechnological developments.

show abstract

“…In particular, the ER constitutes an attractive compartment possessing the machinery to perform several posttranslational modifications and has low protease content. Not reported [60] Floss et al Targeting proteins to protein bodies or oil bodies is also useful as yields are improved and purification steps are simplified [54,55].…”

Section: Nuclear Stable Expression Approachesmentioning

confidence: 99%

An overview of tuberculosis plant-derived vaccines

Rosales‐Mendoza¹,

Ríos-Huerta²,

Angulo³

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

Tuberculosis (TB) is a leading fatal infectious disease to which the current BCG vaccine has a questionable efficacy in adults. Thus, the development of improved vaccines against TB is needed. In addition, decreasing the cost of vaccine formulations is required for broader vaccination coverage through global vaccination programs. In this regard, the use of plants as biofactories and delivery vehicles of TB vaccines has been researched over the last decade. These studies are systematically analyzed in the present review and placed in perspective. It is considered that substantial preclinical trials are still required to address improvements in expression levels as well as immunological data. Approaches for testing additional antigenic configurations with higher yields and improved immunogenic properties are also discussed.

show abstract

Seeds as a Production System for Molecular Pharming Applications: Status and Prospects

Cited by 35 publications

References 135 publications

The potential of plant systems to break the HIV‐TB link

The potential of plant systems to break the HIV‐TB link

Molecular farming on rescue of pharma industry for next generations

An overview of tuberculosis plant-derived vaccines

Contact Info

Product

Resources

About